Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease

Schaefer, Martin; Sarkar, Rahul; Knop, Viola; Effenberger, Susanne; Friebe, Astrid; Heinze, Loni; Spengler, Ulrich; Schläepfer, Thomas E.; Reimer, Jens; Buggisch, Peter; Ockenga, Johann; Link, R.; Rentrop, Michael; Weidenbach, H; Fromm, Gwendolyn; Lieb, Klaus; Baumert, Thomas F.; Heinz, Andreas; Discher, Thomas; Neumann, Konrad; Zeuzem, Stefan; Berg, Thomas

doi:10.7326/0003-4819-157-2-201207170-00006

Cited by 59 publications

(52 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported that depressive symptoms are common in early stages of IFN-based treatment121314 and return to normal after the end of IFN-based treatment 1516. Most studies evaluated the extent of depressive symptoms only at selected time points; for example, at weeks 4, 12, 24, 36, and 48 of IFN-based treatment 16.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C

Choi

Kim

Sohn

et al. 2017

Psychiatry Investig

View full text Add to dashboard Cite

ObjectiveThe aims of this prospective study were to investigate temporal changes in mood status and distress level, as well as the development of depression, during pegylated interferon (PEG-IFN)-based treatment of patients with chronic hepatitis C (CHC). We also explored whether baseline demographic, psychiatric, and personality traits predicted the evolution of depression.MethodsCHC patients without depression were screened with laboratory tests; psychiatric interviews; and evaluations of mood symptoms, level of distress, and personality traits. A total of 67 treatment-naïve patients with CHC were consecutively treated with PEG-IFN-α-2a plus ribavirin for 48 (genotype 1, n=29) or 24 (genotype 2, n=38) weeks. Patients were followed prospectively every 4 weeks during the treatment period.ResultsSeven patients (10.4%) were diagnosed with major depressive disorder (MDD), and eight (11.9%) developed subsyndromal depression. Times to onset of MDD and subsyndromal depression were 6.67±5.01 and 11.11±5.58 weeks, respectively, after initiation of treatment. Patients who developed MDD had significantly increased fatigue and anxiety and poor psychological well-being during the course of treatment. Pretreatment subthreshold mood symptoms were a significant predictor of depression.ConclusionAn early psychiatric assessment may be helpful in improving psychological well-being in those with CHC, leading to adherence to PEG-IFN-based treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Most studies evaluated the extent of depressive symptoms only at selected time points; for example, at weeks 4, 12, 24, 36, and 48 of IFN-based treatment 16. In a recent study, Loftis et al11 evaluated depressive symptoms in patients with CHC biweekly during the first 16 weeks of IFN-based treatment.…”

Section: Introductionmentioning

confidence: 99%

Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C

Choi

Kim

Sohn

et al. 2017

Psychiatry Investig

View full text Add to dashboard Cite

show abstract

“…Prophylactic treatment with an SSRI has been proposed before beginning IFN-α treatment, and this appears to cut the incidence of emergent depression approximately in half (6, 7). However, because most patients will not develop a major depressive episode, the risks and potential benefits of starting an SSRI (which can include serious concerns such as retinopathy) should be discussed with the patient.…”

Section: Preventing Depressionmentioning

confidence: 99%

Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies

Lotrich¹

2013

AJP

View full text Add to dashboard Cite

“…Therefore, it is very important to monitor for the emergence of depressive symptomatology as early as possible during the course of the treatment of hepatitis virus infection with interferon, so that an early intervention can be made. Some even suggest that ''pre-emptive'' antidepressant treatment may be indicated, which may be effective in reducing the incidence and severity of depressive symptoms (Schaefer et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Supportive psychotherapy of a psychodynamic orientation as an adjunctive treatment for drug-induced depression: A case study

Agatsuma¹

2013

International Forum of Psychoanalysis

View full text Add to dashboard Cite

Treatment for drug-induced depression usually consists of cessation or reduction of the causative agent and psychopharmacologic management. In addition, psychotherapy can be useful as an adjunctive treatment. The author presents case material related to a young woman with an inborn physical illness, who became depressed during the course of interferon treatment for a medical complication, hepatitis virus infection. In addition to the cessation of interferon and pharmacologic management, supportive psychotherapy of a psychodynamic orientation was started in order to address the patient's low self-esteem and anxiety about her future. During the course of psychotherapy, it was understood that the premature cessation of interferon was, to her, a narcissistic injury. It was also important to explore the meanings of her inborn illness and her guilty feelings. After reviewing various formulations of depression, the author discusses the case material from an integrative perspective, which describes vicious cycles of depression.

show abstract

Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease

Abstract: Roche Pharma and Lundbeck.

Cited by 59 publications

References 32 publications

Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C

Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C

Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies

Supportive psychotherapy of a psychodynamic orientation as an adjunctive treatment for drug-induced depression: A case study

Contact Info

Product

Resources

About